PHARMA
The future of pharma is open source
The top 20 pharma companies in the world use Posit
We help bring life-changing medicines to market — faster, safer, and with greater efficiency
We are committed to sustaining the open-source data science and scientific research ecosystem through healthy vendor relationships. That's why 100% of the top 20 pharmaceutical companies trust Posit for drug discovery and development.
We work with the industry's top data science teams to develop, maintain, and advance the Pharmaverse, a package ecosystem built specifically for clinical workflows.
No one knows more about open source in the enterprise than us. Posit's enterprise toolchain serves as a foundational component for Statistical Computing Environments across the industry, ensuring reproducibility, scalability, and security.
“We cannot influence whether or not a study reads out positively in the end. But if it does, that basically means it's time for that submission, which uses R and Open Source as its backbone, to get submitted to the Health Authority. And actually, there's one Phase Three trial we have in Oncology which is already on the R platform.”
Thomas Neitmann
Senior Data Scientist at Roche
Posit partners with the world's largest pharma companies to build packages for clinical reporting
ROCHE | GSK
61%
Janssen
45%
ValidationHub
56%
ROCHE | Novartis
51%
Why Posit for drug discovery and development
Open source makes innovation the standard at every go/no-go checkpoint, shortening the feedback loop on decisions in clinical trials by months. Use Shiny applications to analyze clinical trial data in interactive ways. Feed dashboards that display the status of trials in real-time. Leverage packages designed specifically for pharma to streamline clinical workflows. Open source gets you from thousands of compounds to one leading molecule faster than ever.
Every clinical trial produces hundreds of outputs. Pharmaceutical companies are partnering to build and use packages that help programmers automate this process. Open source can get you to SDTM/ADaM datasets quicker. And once you have SDTM/ADaM datasets, use open source for better validation and quality control.
Open source can and should be used in regulatory submissions. Leading pharmaceutical companies are collaborating with regulatory agencies like the FDA more than ever before, providing guidance and obtaining feedback on how open source should be used for submissions.
Real impact, made possible by only open source and Posit
Posit Team
Our end-to-end platform
Posit tools support the leading packages in clinical reporting
